Update shared on31 Jul 2025
With the consensus analyst price target and key valuation metrics such as the discount rate and future P/E ratio remaining effectively unchanged, analysts see little shift in OraSure Technologies’ fair value, which stays at $6.00.
What's in the News
- Ron Zwanziger, supported by a Wall Street investor, made an unsolicited all-cash takeover offer for OraSure Technologies at $3.50-$4.00 per share, which the board rejected without discussions; this was Zwanziger’s second unsuccessful approach.
- OraSure launched HEMAcollect™ PROTEIN, a blood collection tube for proteomic researchers, offering improved sample preservation, compatibility with multiple technologies, and anticipated operational/financial efficiencies.
- OraSure was added to both the Russell 2000 Defensive Index and Russell 2000 Value-Defensive Index.
- The company entered a commercial collaboration with Targeted Genomics for expanded consumer access to at-home celiac genetic testing, utilizing ORAcollect® Dx saliva collection device.
- OraSure provided Q2 FY25 guidance of $28–32 million in core revenues and about $0.5 million in COVID-19 and Risk Assessment testing revenues and reported no share repurchases in early 2025.
Valuation Changes
Summary of Valuation Changes for OraSure Technologies
- The Consensus Analyst Price Target remained effectively unchanged, at $6.00.
- The Discount Rate for OraSure Technologies remained effectively unchanged, at 7.16%.
- The Future P/E for OraSure Technologies remained effectively unchanged, moving only marginally from 28.23x to 28.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.